Advertisement

Topics

Cellectis gets FDA go-ahead to restart fatal CAR-T trial

04:45 EST 8 Nov 2017 | pharmaphorum

The FDA has said Cellectis can restart trials of its ‘off-the-shelf’ CAR-T cancer immunotherapy, after revising protocols in a trial that killed one patient and left another with life-threatening complications. UCART123 is a CAR-T therapy prod...

Original Article: Cellectis gets FDA go-ahead to restart fatal CAR-T trial

NEXT ARTICLE

More From BioPortfolio on "Cellectis gets FDA go-ahead to restart fatal CAR-T trial"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...